Business Summary
Structure Therapeutics is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics targeting G-protein coupled receptors (GPCRs) for chronic diseases with unmet medical need. The company leverages a differentiated structure-based drug discovery platform combined with computational chemistry (via collaboration with Schrödinger) to convert biologic and peptide therapies into oral small molecules. Its lead candidate, aleniglipron (GSBR-1290), is an oral GLP-1 receptor agonist for obesity that demonstrated 11.3% placebo-adjusted weight loss at 120mg in Phase 2b (ACCESS study), with Phase 3 planned for H2 2026.
Products & Services
- Aleniglipron (GSBR-1290): Oral small molecule GLP-1R agonist for obesity/overweight — Phase 2b completed, Phase 3 planned H2 2026; 15.3% weight loss at 240mg in ACCESS II exploratory study
- ACCG-2671: Oral small molecule amylin receptor agonist — Phase 1 clinical development; potential first-in-class oral amylin for obesity
- ACCG-3535: Second amylin development candidate — preclinical -...
AI-generated summary of Item 1 (Business) from the 10-K filed Feb 26, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q2 2026| Largest holders | Reported value |
|---|---|
| FMR LLC | $419.2M |
| WELLINGTON MANAGEMENT GROUP LLP | $396.1M |
| Avoro Capital Advisors LLC | $351.8M |
| Jupiter Topco LLC | $279.3M |
| Deep Track Capital LP | $254.4M |
Annual results · 10-K
Fiscal 2025- Net loss
- -$141.2M
As reported in the fiscal 2025 annual report.
Securities
| CUSIP | Security | Type |
|---|---|---|
| 86366E106 | GPCR STRUCTURE THERAPEUTICS INC | Adr |
Insider trades · Form 4
Latest filings
- Crespo Blas Coll 2026-09-22 Sell
- Xichen Lin 2026-09-03 Sell
- Xichen Lin 2026-08-20 Sell
- John Joseph Berrios 2026-08-07 Award
- Xichen Lin 2026-08-05 Sell
5%+ holders · 13D/G
5 filers| Filer | % of class | Filed |
|---|---|---|
| FMR LLC 13G | 13.2% | 2026-08-06 |
| Deep Track Capital LP 13G | 6.0% | 2026-02-13 |
| WELLINGTON MANAGEMENT GROUP LLP 13G | 10.1% | 2026-02-10 |
| JANUS HENDERSON GROUP PLC 13G | 7.7% | 2025-11-14 |
| Avoro Capital Advisors LLC 13G | 9.4% | 2025-11-14 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.